background
fibrinogenlik
protein
new
member
fibrinogenlik
famili
recent
identifi
novel
immunosuppress
molecul
aim
purpos
work
investig
intestin
peripher
express
patient
inflammatori
bowel
diseas
ibd
mainli
ulcer
coliti
uc
crohn
diseas
cd
method
express
mucos
biopsi
three
group
uc
group
n
cd
group
n
control
group
n
detect
immunohistochemistri
concentr
plasma
uc
patient
cd
patient
control
analyz
enzymelink
immunosorb
assay
western
blot
protein
realtim
fluoresc
quantit
pcr
mrna
express
peripher
mononuclear
cell
perform
correl
express
diseas
type
activ
locat
measur
laboratori
data
includ
creactiv
protein
crp
erythrocyt
sediment
rate
esr
examin
result
intestin
peripher
protein
data
show
express
significantli
upregul
uc
cd
patient
compar
control
p
express
higher
uc
cd
patient
activ
diseas
inact
diseas
p
moreov
mrna
express
significantli
higher
patient
activ
diseas
inact
diseas
p
express
protein
correl
diseas
activ
indic
crp
level
esr
level
conclus
express
upregul
ibd
patient
activ
diseas
measur
may
use
help
biomark
understand
immunopathogenesi
assess
ibd
inflammatori
bowel
diseas
ibd
chronic
relaps
remit
inflammatori
condit
gastrointestin
gi
tract
mainli
includ
two
clinic
entiti
ulcer
coliti
uc
crohn
diseas
cd
frequent
associ
system
manifest
increas
risk
colon
cancer
recent
decad
continu
trend
greater
incid
preval
ibd
throughout
world
particularli
east
asia
attent
must
paid
effect
diagnosi
treatment
ibd
although
exact
caus
mechan
ibd
complet
elucid
prevail
hypothesi
ibd
pathogenesi
diseas
occur
genet
suscept
individu
result
complex
interact
among
environment
factor
microbi
factor
intestin
immun
system
furthermor
accumul
evid
indic
inappropri
persist
immun
respons
central
develop
major
type
ibd
excess
inflammatori
stimuli
mediat
inadequ
low
function
number
regulatori
compon
downregul
mucos
immun
respons
lead
chronic
progress
inflammatori
condit
eventu
intestin
tissu
damag
fibrinogenlik
protein
also
known
fibroleukin
first
clone
cytotox
lymphocyt
classifi
member
fibrinogen
superfamili
homolog
fibrinogen
b
c
chain
origin
describ
immun
coagul
abil
gener
thrombin
directli
implic
pathogenesi
sever
inflammatori
disord
includ
viral
hepat
experiment
arthriti
recent
demonstr
effector
molecul
regulatori
cell
treg
cell
may
bind
fc
gamma
receptor
fccr
express
antigenpres
cell
apc
inhibit
matur
dendrit
cell
dc
induc
apoptosi
b
cell
eventu
result
reduc
abil
induc
alloreact
cell
prolifer
find
collect
indic
potent
immunosuppress
properti
suggest
involv
immunopathogenesi
ibd
felt
necessari
investig
express
patient
ibd
discuss
involv
studi
perform
depart
gastroenterolog
hepatolog
first
affili
hospit
wenzhou
medic
univers
decemb
decemb
mucos
biopsi
specimen
obtain
macroscop
inflam
area
patient
uc
n
cd
n
normal
control
nc
n
ie
normal
area
healthi
subject
patient
colon
polyp
tabl
match
peripher
blood
avail
patient
uc
n
cd
n
depart
gastroenterolog
hepatolog
first
affili
hospit
wenzhou
medic
univers
enrol
januari
april
tabl
compar
sampl
normal
control
recruit
healthi
blood
donor
visitor
hospit
ward
normal
hospit
personnel
diagnosi
uc
cd
base
standard
criteria
uc
cd
patient
activ
diseas
enrol
studi
receiv
immunomodulatori
medic
diseas
uc
patient
inact
diseas
undergo
mainten
treatment
lowdos
acid
other
stop
drug
cd
patient
inact
diseas
undergo
mainten
treatment
lowdos
azathioprin
lowdos
azathioprin
methylprednisolon
diseas
activ
uc
patient
evalu
use
truelovewitt
criteria
statist
purpos
classif
left
side
coliti
uc
colon
cd
total
coliti
uc
ileum
colon
cd
left
side
coliti
uc
colon
cd
total
coliti
uc
ileum
colon
cd
quantit
modifi
activ
diseas
defin
score
inact
diseas
score
patient
cd
sever
diseas
classifi
accord
cdai
score
activ
diseas
defin
cdai
score
inact
diseas
cdai
score
diseas
activ
evalu
time
sampl
collect
standard
laboratori
data
includ
red
white
blood
cell
count
hemoglobin
hematocrit
platelet
count
erythrocyt
sediment
rate
alifax
itali
creactiv
protein
beckman
coulter
detect
kit
japan
routin
measur
patient
uc
cd
mucos
biopsi
specimen
fix
paraform
process
paraffin
section
immunohistochem
stain
section
initi
deparaffin
xylen
rehydr
ethanol
water
nonspecif
bind
block
sequenti
incub
section
citrat
buffer
min
min
hydrogen
peroxidas
solut
min
follow
normal
goat
serum
pb
min
thereaft
section
incub
mous
antihuman
monoclon
antibodi
abnova
taiwan
dilut
pb
h
wash
pb
section
incub
immunoperoxidaseconjug
rabbit
igg
fraction
mous
igg
fc
zhongshan
beij
china
min
follow
three
wash
pb
final
section
incub
diaminobenzidin
chromagen
counterstain
hematoxylin
neg
control
use
experi
evalu
express
ten
random
field
across
section
select
semiquantit
analysi
mean
absorb
magnif
blood
sampl
drawn
fast
rest
period
min
nontraumat
venipunctur
perform
standard
manner
train
oper
blood
ml
drawn
test
tube
ml
citrat
within
h
sampl
collect
sampl
centrifug
min
store
plastic
tube
serial
analysi
plasma
thaw
immedi
water
bath
min
accord
manufactur
instruct
plasma
concentr
measur
use
commerci
avail
enzymelink
immunosorb
assay
elisa
biolegend
usa
peripher
blood
obtain
peripher
blood
mononuclear
cell
pbmc
isol
use
ficol
densiti
gradient
solarbio
shanghai
china
western
blot
analysi
lysat
protein
lg
extract
pbmc
load
sdspolyacrylamid
gel
separ
protein
transfer
nitrocellulos
nc
membran
membran
block
probe
monoclon
antibodi
abnova
taiwan
dilut
milk
tbst
wash
tbst
blot
incub
secondari
antibodi
conjug
horseradish
peroxidas
biosharp
hefei
china
immunoreact
band
detect
enhanc
chemiluminesc
ecl
reagent
pierc
biotechnolog
shanghai
china
protein
level
normal
gapdh
determin
densitometr
analysi
use
quantiti
one
version
total
rna
isol
pbmc
use
trizol
reagent
invitrogen
shanghai
china
accord
manufactur
procedur
concentr
puriti
rna
determin
measur
absorb
nm
subsequ
cdna
synthes
taigen
biotechnolog
china
nucleotid
sequenc
primer
pcr
amplif
bp
fragment
sens
primer
actgt
antisens
primer
tcc
amplifi
bp
fragment
gapdh
use
intern
control
ensur
equal
load
forward
primer
tcccat
revers
primer
protocol
studi
approv
clinic
research
ethic
committe
first
affili
hospit
wenzhou
medic
univers
subject
enrol
studi
inform
given
written
consent
result
express
mean
sd
statist
analysi
conduct
spss
softwar
continu
measur
among
three
diagnost
group
compar
oneway
anova
posthoc
multipl
comparison
perform
use
dunn
test
test
use
comparison
diseas
activ
diseas
locat
among
differ
group
associ
express
diseas
activ
indic
laboratori
data
includ
crp
level
esr
level
examin
nonparametr
correl
spearman
r
level
p
consid
statist
signific
fig
c
diseas
locat
uc
cd
patient
differ
associ
level
clinic
indic
activitytruelovewitt
uc
cdai
cd
r
p
r
p
respect
furthermor
enhanc
level
correl
crp
level
uc
cd
patient
r
p
r
p
respect
level
esr
r
p
r
p
respect
addit
two
cd
patient
activ
diseas
underw
antitumor
necrosi
factor
tnfa
azathioprin
therapi
followedup
regularli
studi
level
one
patient
ngml
period
treatment
week
respect
level
anoth
patient
ngml
treatment
ngml
week
ngml
week
ngml
week
treatment
decreas
level
parallel
clinic
cutdown
cdai
score
fig
western
blot
analysi
reveal
protein
express
normal
gapdh
pbmc
ci
patient
uc
ci
patient
cd
compar
ci
control
markedli
elev
patient
cd
comparison
normal
control
p
statist
signific
differ
patient
uc
control
fig
mrna
express
significantli
higher
uc
cd
patient
activ
diseas
inact
diseas
p
fig
c
howev
mrna
express
lower
patient
inact
diseas
control
inact
uc
vs
nc
inact
cd
vs
nc
p
fig
c
intestin
lumen
home
strain
bacteria
gi
mucos
immun
system
must
strike
delic
homeostat
balanc
maintain
toler
toward
commens
microflora
remain
pois
mount
aggress
immun
respons
invad
pathogen
normal
condit
epitheli
barrier
continu
sampl
antigen
lumen
present
lymphocyt
peyer
patch
promot
toler
encount
invas
pathogen
apc
mucosa
includ
macrophag
dc
intestin
epitheli
cell
phagocytos
invad
pathogen
present
compon
naiv
cell
cell
undergo
activ
differenti
effector
phenotyp
ie
regulatori
phenotyp
ie
treg
effector
thelper
cell
mount
specif
immun
respons
express
uniqu
cytokin
combat
invad
pathogen
treg
cell
suppress
inflamm
restor
homeostasi
mucos
tissu
express
regulatori
cytokin
exampl
transform
growth
factor
tgfb
howev
inher
defect
mucos
immun
system
ibd
patient
although
exact
natur
defect
identifi
mount
evid
indic
ibd
occur
presenc
dubiou
antigen
like
normal
resid
lumin
bacteri
andor
foodderiv
initi
dysregul
immun
respons
within
intestin
mucosa
eventu
develop
chronic
intestin
inflamm
furthermor
sustain
interest
import
treg
cell
ibd
seem
fewer
circul
treg
cell
present
patient
activ
ibd
insuffici
increas
intestin
mucosa
subsequ
research
suggest
increas
apoptosi
treg
cell
ibd
revers
antitnfa
therapi
would
critic
factor
recurr
diseas
nevertheless
clearli
core
mechan
tregmedi
suppress
still
controversi
although
tgfb
molecul
report
account
regulatori
activ
treg
cell
antibodi
molecul
case
effect
minim
inhibit
treg
cell
activ
vitro
recent
find
reveal
possibl
import
contribut
suppress
activ
treg
cell
consist
aa
contain
ctermin
fibrinogenrel
domain
fred
highli
conserv
region
characterist
protein
within
fibrinogen
superfamili
function
divers
protein
includ
fibrinogen
tenascin
angiopoietin
ficolin
shown
immunoregulatori
activ
similarli
much
research
recent
reveal
secret
cell
also
immunomodulatori
activ
mrna
increas
treg
cell
along
mrna
sever
known
treg
suppress
effector
molecul
furthermor
shalev
et
al
report
suppress
activ
cell
significantli
impair
antibodi
complet
inhibit
activ
treg
cell
vitro
consist
contribut
activ
treg
cell
target
delet
gene
led
increas
immun
reactiv
dc
cell
b
cell
develop
autoimmun
glomerulonephr
age
regulatori
activ
also
contribut
inhibit
allograft
reject
pathogenesi
experiment
human
viral
infect
includ
hiv
sever
acut
respiratori
syndrom
sar
hepat
b
viru
hepat
c
viru
evid
strongli
support
hypothesi
effector
molecul
treg
cell
mechan
wherebi
exert
immunomodulatori
activ
demonstr
liu
et
al
may
bind
fccriib
express
apc
inhibit
dc
matur
induc
b
cell
apoptosi
eventu
result
reduc
abil
induc
alloreact
cell
prolifer
given
ibd
share
immunolog
featur
autoimmun
diseas
extent
logic
hypothes
immunomodulatori
activ
may
also
involv
immunopathogenesi
ibd
howev
studi
demonstr
intestin
peripher
express
significantli
higher
uc
cd
patient
activ
diseas
decreas
inact
diseas
moreov
express
posit
correl
diseas
activ
indic
crp
level
esr
level
upregul
uc
cd
patient
activ
diseas
may
insuffici
compens
secret
treg
cell
fail
counter
chronic
activ
effector
cell
lead
inappropri
immun
respons
ibd
reduc
express
patient
inact
diseas
may
success
treatment
includ
immun
modifi
antitnfa
therapi
antiinflammatori
treatment
made
defici
treg
cell
revers
defici
exert
suffici
suppress
subset
lymphocyt
multipl
suppress
molecul
assumpt
agreement
result
maul
et
al
report
decreas
peripher
treg
cell
insuffici
increas
intestin
lesion
also
consist
therapeut
strategi
immun
modifi
antitnfa
therapi
use
conclus
result
studi
express
ibd
import
theoret
implic
understand
immunopathogenesi
ibd
practic
implic
therapi
may
help
biomark
pathogenesi
ibd
assess
diseas
confirm
initi
investig
involv
among
patient
ibd
